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Cardiovascular disease (CVD) remains the single leading cause of death in both men and women. A large proportion of the
population with CVD will die with a diagnosis of congestive heart failure (CHF). It is becoming increasingly recognized that sex
diﬀerences exist in the etiology, development, and outcome of CHF. For example, compared to male counterparts, women that
present with CHF are typically older and have systolic cardiac function that is not impaired. Despite a growing body of literature
addressing the underlying mechanisms of sex dimorphisms in cardiac disease, there remain signiﬁcant inconsistencies reported in
these studies. Given that the development of CHF results from the complex integration of genetic and nongenetic cues, it is not
surprising that the elucidation and subsequent identiﬁcation of molecular mechanisms remains unclear. In this review, key aspects
of sex diﬀerences in CVD and CHF will be highlighted with an emphasis on some of the unanswered questions regarding these
diﬀerences. The contention is presented that it becomes critical to reference cellular mechanisms within the context of each sex to
better understand these sex dimorphisms.
1.Introduction
Risk assessment for cardiovascular disease (CVD) begins
with a close examination of genetic modiﬁers (age, sex,
family history) and nongenetic environmental modiﬁers
(smoking, alcohol, diet). The prevailing thought among
contemporary investigators is that the severity of CVD
dependsoncontributionsfrombothgeneticandnon-genetic
factors. Of the genetic factors, much attention has been
paid to biological sex or gender as a potent modiﬁer of
cardiovascular health. (It is generally accepted that biologic
sex is deﬁned as being chromosomally male or female while
gender is a function of biologic sex, culture, behavior, and
environment. For simplicity, we have decided to use the term
sex in this review.) Although the vast majority of clinical and
laboratory studies have been carried out in males, there is
a growing body of literature directly addressing sex-speciﬁc
diﬀerences in cardiovascular disease and outcomes. Pre-
menopausalwomenconsistentlyhaveabetterprognosisthan
men in response to hypertension, aortic stenosis, myocardial
infarction (MI), and hypertrophic cardiomyopathies [1–
3]. The hearts of women with these disorders maintain
adequate or elevated cardiac function whereas men typically
demonstrate increased chamber dilation and wall thinning,
both of which contribute to the observed poor contractility
[4, 5]. The same is also true for congestive heart failure
(CHF); women have better survival than men even when
adjusted for severity of cardiac function [6, 7] and the long-
term prognosis is better for women than for men [8, 9].
Becauseofthissexdiﬀerence,estrogenhasbeenproposed
as a major cardioprotective agent in premenopausal women.
However, a recent study showed that hormone replace-
ment therapy (HRT) in postmenopausal women increased
their CVD risk [10] forcing reconsideration of estrogen as
being cardioprotective. Moreover, it seems unlikely that the
male/female dimorphisms in CVD can be attributed to a
single factor such as estrogen. This review will not explicitly
discuss the impact of estrogen on cardiovascular health and
disease as we have addressed this previously [11].
Nevertheless, estrogen is positioned to play a unique role
in CVD since estrogen can respond to environmental, non-
genetic cues and subsequently impact genetic expression
[11]. Consequently, diﬃculty arises when attempting to
understand how environmental factors, such as blood lipid
proﬁles, impact CVD in men and women. For example,
althoughstatintherapyreducescardiovasculareventsinboth2 Journal of Biomedicine and Biotechnology
men and women equally, women do not have the same
reductions in mortality and stroke as their male counterparts
[12]. To further complicate matters, plasma triglycerides are
better predictors of cardiovascular risk in women, whereas
LDL-cholesterol concentration is a stronger predictor in
men [13–16]. However, this discrepancy disappears in older,
postmenopausal (estrogen-free) women where LDL levels
exceed those in men and become better correlated with
cardiovascular risk [17, 18].
Consequently, elucidating the cellular and molecular
mechanisms of cardiac disease progression and how it diﬀers
between the sexes becomes tantamount to the discovery of
clinical treatment strategies. Despite an increasing knowl-
edge regarding the sex dimorphisms in the pathophysiology
of cardiac disease, which we have extensively reviewed
previously [11], many inconsistencies remain regarding the
identiﬁcation of these diﬀerences. More importantly, as
will be discussed below, interpretation of these mechanisms
explicitly depends on context, that is, how these underlying
mechanisms act within each sex. In this review, we will focus
on these inconsistencies in sex-speciﬁc diﬀerences in cardiac
disease development. Considering that CHF is characterized
by progressive impairments in cardiac function and con-
tractility and that pharmacological manipulation of cardiac
contractility is the predominant therapeutic strategy, there
will be a particular emphasis on detailing the underlying
contractile function in a sex speciﬁc manner.
2. HeartFailureinWomen
This review is not intended to be a comprehensive or clinical
exposition on the etiology, diagnosis, and treatment of CHF
in women; other reports are available for this information
(see [19]). Nevertheless, a few key facts require highlighting.
Of all-cause mortality in women, CVD ranks as the highest
[20]. Over one-third of CVD deaths in women are due to
CHF. Interestingly, the Rotterdam Study shows an increasing
incidence and prevalence of CHF for both men and women
with age; yet, the rate in men always exceeds that in women
independentofage[21,22].Inthesamestudy,nodiﬀerences
between men and women were found in heart failure
prognosis [22]. Another publication, citing a self-reported
heart failure survey administered by the National Center
for Health Statistics in 1999, reports a greater prevalence of
heart failure in men than women ages 65–74 but that after
age 74, this diﬀerence signiﬁcantly diminishes [23]. On the
other hand, a recent study reports that idiopathic dilated
cardiomyopathy is a much deadlier disease in women than
in men [24].
In most cases, measures of cardiac contractility are
valuable prognostic indicators in patients with severe CHF
[25, 26]. Data suggest that the risk of death increases with
worsening left ventricular (LV) systolic function [27]. Yet,
when broken down by sex, the data are less conspicuous.
In general, both men and women show increased mortality
associated with impaired LV function [27]. However, more
women than men with CHF present with preserved, not
impaired,L Vs y s t o l i cf u n c t i o n[ 28, 29]. It seems logical to
assert that the increased survival in women over men is
due to this elevated contractile function. However, more
recent studies argue that there is a lack of survival beneﬁt for
patients with preserved LV function as measured by ejection
fraction over patients with impaired systolic function [30,
31]. The suggestion is that the sex dimorphism in CHF
survival may not necessarily be due to diﬀerences in CHF
presentation but, instead, a fundamental diﬀerence in the
ability of the female heart to tolerate the physiological
changes associated with CHF (for review see [19]).
These apparent inconsistent reports underscore the dif-
ﬁculty in interpreting the CHF mortality literature and any
sexual dimorphisms that may be revealed by these studies.
A potentially major source of error contributing to these
discrepancies lies in the deﬁnition of CHF. CHF is an end-
result of many CVD etiologies and it is unclear whether
there are sex diﬀerences in the etiology of CHF [19, 32].
Similarly, the clinical deﬁnition of CHF with preserved
LV systolic function (which presents in over 50% of the
patient population [33]) may be misleading. These patients
typically experience underlying diastolic dysfunction, which,
according to the studies cited above, may lead to similar
mortality rates as those patients with impaired LV function.
The presentation of diastolic dysfunction with preserved
systolic LV function is a clinically relevant phenotype
[33, 34]. Impairments in LV relaxation, distensibility, and
stiﬀness are rooted in the cardiac cell and, thus, have
underlying cellular mechanisms [35–37]. The ﬁndings that
more women than men have CHF with normal LV function
indicate that females do not demonstrate a similar risk to
diastolic dysfunction as their male counterparts. To date,
there are no studies directly examining the mechanism of sex
dimorphisms in diastolic dysfunction and CHF.
Since treatment strategies are typically not sex speciﬁc,
the extent and intensity of the medical intervention could
alsoaﬀecttheoutcomeofthesestudies[38,39].Forexample,
when the attainment of recommended LDL cholesterol levels
is the goal, even if appropriate LDL cholesterol levels are
reached, there is no clear evidence that men and women
beneﬁt equally [39, 40]. The ﬁndings with LDL cholesterol
may also reﬂect fundamental sex diﬀerences in the hydrolysis
of LDL and substrate delivery to cardiomyocytes as elabo-
rated below. Furthermore, studies attempting to delineate
the diﬀerential impact of preserved or impaired LV systolic
function and CHF survival struggle to maintain consistency
with the above parameters. Apart from investigating the
underlying causes of the apparent sex diﬀerences in CHF,
investigators are challenged to ﬁnd appropriate models to
study the impact of sex on the development, response, and
progression of heart disease.
3. Sex DifferencesinCardiacFunction
Considering that cardiac pathophysiology is unique among
men and women, it is reasonable to assume that basal
cardiac physiology is similarly unique among the sexes.
Unfortunately, the data supporting this assertion vary from
study to study and are not clear. Whether examining humans
or rodents, the anatomical arrangement of the heart and
peripheral cardiovascular system is identical between malesJournal of Biomedicine and Biotechnology 3
and females. However, the size of the female heart is smaller
than age- and race-matched men [41]. This appears to be
consistentamongspecies;thelargertheanimal,thelargerthe
heart.Ifcardiacphysiologyisproportionatetoorganismsize,
it is not surprising to ﬁnd that the diﬀerence is eliminated
when heart size is adjusted for body mass. We have examined
cardiac morphometrics in mice detailing similar ﬁndings
[42, 43].
It has been suggested that male and female hearts begin
with an equivalent number of cardiac myocytes and, there-
fore, the diﬀerence in cardiac size, although proportional to
bodymass,isduetolargermyocytesizeinmalescomparedto
females [44–46]. Considering that males are typically larger
in body mass, the corresponding increase in myocyte size is
most likely a result of diﬀerences in physiological demand.
However, since prevailing systemic pressures are equivalent
among men and women, males and females utilize unique
mechanisms to maintain homeostasis as discussed by Huxley
(2007) [47].
Diﬀerences in cardiac myocyte size translate into diﬀer-
ences in ventricular chamber dimensions. Looking at a study
population(57yearsofageonaverage)freeofclinicallyovert
cardiovascular disease, all volumetric parameters measured
by magnetic resonance imaging (MRI) are elevated in males,
even when adjusted for subject height or body surface
area [48, 49]. In these same studies, no diﬀerences in LV
functionalparametersareevidentalthoughthesedataarenot
always consistent [47–49].
In a more invasive approach employed by Shioura et
al. (2008) [50] male and female mice were instrumented
with a conductance catheter able to accurately and simul-
taneously measure LV pressure and volume. The authors
demonstrate similar baseline hemodynamic parameters in
male and female mice. More importantly, this is the ﬁrst
study that shows no signiﬁcant diﬀerences between male
and female hearts using the end-systolic pressure-volume
relationship (ESPVR) to index ventricular contractility. The
ESPVR provides a measure of ventricular contractile state
that is independent of heart rate and, more importantly,
loading conditions within the physiological range [51–53].
In addition, a measure of diastolic function as indexed by
theend-diastolicpressure-volumerelationship(EDPVR)can
be derived from these studies [50]. Using these parameters
of ventricular function, these investigators evaluated male
and female mice at diﬀerent timepoints following an MI.
Both male and female mice demonstrate an immediate
deterioration in function following MI. Ten weeks post
MI, female hearts improve contractility to baseline levels
as measured by the ESPVR while male hearts do not
[50]. Female mice show a similar attenuation in volumetric
parameters. Interestingly, only female hearts display diastolic
dysfunction but only at an early timepoint.
Interestingly, the authors document similar baseline vol-
umetricparametersinbothmaleandfemaleheartsusingthis
technique. Considering that male hearts are typically larger
than female hearts under normal physiological conditions,
onewouldpredictasexdimorphisminend-systolicandend-
diastolic volumes as indicated in the human MRI studies.
Although this most likely would not alter fundamental
contractile characteristics, it does point out the limitations
of these studies regarding absolute volume calculations [54].
Nevertheless, many noninvasive techniques such as MRI or
echocardiography harbor more signiﬁcant limitations when
measuring cardiac contractility [55, 56]. Using the pressure-
volume technique, investigators will be able to monitor
cardiac function and contractility with and without disease
and/or disease interventions in the appropriate context;
that is, within the same sex. Thus, this paper represents
a signiﬁcant advancement and establishes the benchmark
for detecting sex dimorphisms in cardiac function under
normal and diseased states. More importantly, it predicts
a cellular mechanism underlying changes in contractile
function detailed below.
4.CardiacCellularDynamicsandContractility
Despite the technical limitations, the use of the ESPVR and
the EDPVR, and resultant measures from this approach,
provides an important link to cardiac cellular dynamics.
When addressing sex dimorphisms in cardiac physiology
and pathophysiology, it becomes necessary to integrate
intact ventricular function (systolic and diastolic) with
myoﬁlament function, the ultimate determinant of cellular
dynamics. The ability to maintain contractile force at a given
cytosolic Ca2+ concentration is in part determined by the
sensitivity of the myoﬁlaments to Ca2+ with the output of
tension development as the endpoint. At the cellular level,
this type of analysis provides an index of cardiac contractility
and is directly related to contractility as indexed by the
ESPVR (Figure 1). The reason is that we and others have
proposed that a fundamental association exists between
myoﬁlament Ca2+-sensitivity, sarcomere length and tension
of the cardiac cell and pressure and volume in the intact
ventricle.Inthiscontext,therelationshipbetweenlengthand
tension (end-systolic tension-length relationship; ESTLR) of
isolated cardiac muscle preparations determines the shape of
the pressure-volume relationship at end-systole (ESPVR) of
the intact ventricle (Figure 1)[ 57–59].
However, the literature examining sex dimorphisms in
myoﬁlament function is equivocal. Some studies illustrate
that isolated cardiac muscle preparation from female hearts
responds with greater tension than males at a given amount
of Ca2+ indicative of enhanced Ca2+-sensitivity [60, 61].
Other studies document the exact opposite results; female
hearts are less sensitive to Ca2+; that is, isolated cardiac
muscle preparations respond with lower tension than males
a tag i v e nl e v e lo fC a 2+ [62, 63]. We have similarly found
a reduced Ca2+-sensitivity in the hearts of female mice
compared to males (unpublished observations). In support
of reduced myoﬁlament Ca2+-sensitivity in females, the
loss of estrogen by ovariectomy increases the sensitivity
of the myoﬁlaments to Ca2+ [64–66]. Interestingly, loss of
testosterone in males reduces Ca2+-sensitivity, which can be
reversed by testosterone replacement [67]. Using a similar
approach, another study shows no diﬀerences in Ca2+-
sensitivity between male and female cardiac trabeculae [68].
In this same study, female trabeculae fail to generate equiv-
alent levels of force with increasing stimulating frequencies4 Journal of Biomedicine and Biotechnology
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Figure 1: Relationship between Ca2+-sensitivity, length, and tension to the pressure-volume relationship. The sensitivity of cardiac
myoﬁlaments to Ca2+ indicates the contractile state of the cardiac muscle cell. The relationship between Ca2+ and tension is illustrated in the
bottom panel labeled Ca2+-sensitivity of tension. There exists a unique Ca2+-sensitivity of tension relationship at each length (SL: sarcomere
length) and these relationships can be used to create the Length-tension relationship (upper left panel) as indicated by the arrows. The
Length-tension relationship can alternatively be called the end-systolic tension-length relationship (ESTLR) and is the underlying cellular
mechanism of the end-systolic pressure-volume relationship (ESPVR; upper right panel).
compared to males. This eﬀect is exaggerated at longer
lengths and at higher extracellular [Ca2+].
Thereasonsfortheseinconsistenciesaremultifold.Ca2+-
responsiveness of isolated cardiac muscle was determined
using either chemically permeabilized preparations or car-
diac muscle preparations with membranes intact. Chemical
permeabilization removes membrane-bound organelles that
include the Ca2+-handling machinery. Therefore, it is not
surprising that diﬀerences in Ca2+-sensitivities are observed
since sex dimorphisms exist in excitation-contraction cou-
pling, which remains intact in nonpermeabilized prepara-
tions [69–71]. Additionally, 2 critical confounding factors
are diﬀerences in (1) species (rats, mice, or cats) and (2)
ages of the animals used in the studies described above.
Although the impact of species on myoﬁlament function
is rather apparent, age-dependent changes highlight how
signaling components within the cardiac myocyte can alter
myocellular function. Similarly, the impact of estrogen
and/or testosterone predicts a potential sex-dimorphism
in intracellular cardiac signaling. This becomes especially
important in the context of sex, cardiac disease, and disease
progression.
There are numerous signaling mediators in the cardiac
cell, many of which target myoﬁlament proteins and are
involved in excitation-contraction coupling, growth signal-
ing, and other processes involved in cellular remodeling as
occured with cardiac disease progression [72–74]. Predicting
ap r i o r ihow sex impacts these signaling pathways, which, in
turn, impacts contractile properties and cellular remodeling
to disease, becomes problematic. Moreover, it is not known
how sex, and potentially sex hormones, inﬂuences these sig-
naling pathways in the short- and long-term. Consequently,
an integrated approach to understanding how signaling
pathways modulate both cellular remodeling and contractile
dynamics in a sex-speciﬁc manner is required of future
investigations, again pointing to the context in which these
studies must be performed and interpreted.
To illustrate this contention and the complexity of
how sex can modify signaling at multiple steps, we can
use β-adrenoceptor stimulation as the model. During a
cardiac insult such as MI, posttranslational modiﬁcation of
myoﬁlament proteins and the subsequent impact on Ca2+-
sensitivity becomes a key mechanism of short- and long-
term remodeling within the cardiac cell [75–77]. Short-
termβ-adrenoceptorstimulationimmediatelyincreasesrates
of relaxation and contraction in the myocardium [78,
79]. This is accomplished by enhancing Ca2+ cycling in
the myocyte through phosphorylation of phospholamban
[79–82], decreasing the sensitivity of the myoﬁlaments to
Ca2+ [83, 84], and accelerating the rate-limiting steps in
the crossbridge cycle [85, 86]. Thus, the integrated short-
term response of β-adrenergic stimulation results fromJournal of Biomedicine and Biotechnology 5
targeting Ca2+ cycling machinery, phospholamban, leading
to enhanced reuptake of Ca2+ by the sarcoplasmic reticulum
[79–82] and direct phosphorylation of contractile proteins,
troponin I, and myosin binding protein C [87, 88]t oa l t e r
contractile mechanics.
Yet, prolonged β-adrenergic stimulation induces patho-
logical hypertrophy, cellular remodeling, and decreased
myoﬁlament protein phosphorylation that leads progressive
deterioration of cardiac function [72, 73, 89, 90]. In a recent
study that investigated the interaction of estrogen and β-
adrenergic stimulation, concomitant exposure of neonatal
ventricular myocytes with norepinephrine (β-adrenergic
agonist) and estrogen mitigated the hypertrophy that occurs
with norepinephrine treatment alone [91]. These data
represent some of the ﬁrst indications that hypertrophic,
pathologic stimulation is directly aﬀected by estrogen and
may be blunted in the presence of estrogen.
Given this deﬁned combinatorial integration of cellular
signaling, the resultant impact on myoﬁlament and intact
ventricular function depends on the species, sex, and
timepoint in disease progression of the animals used in
the study. It is possible that sex dimorphisms exist at each
step in the above signaling pathway leading to a more
hastened worsening of cardiac pathophysiology in males as
compared to females. Yet, the sex-dependent mechanism
of the diﬀerential pathogenesis necessitates an integrative
understanding from the cellular to the whole heart level.
Another example where this integrative approach may
shed major insight can be illustrated in transgenic mice
expressing a mutant myosin heavy chain transgene (R403Q)
corresponding to a human mutation causing hypertrophic
cardiomyopathy (HCM) [43, 92, 93]. We have studied sex
dimorphisms in R403Q mice and characterized some of
the cellular and molecular mechanisms behind the sex
diﬀerences [43, 92]. These include a number of pathologic
indicators such as ﬁbrosis, induction of β-myosin heavy
chain, inactivation of glycogen synthase kinase-3β,a n d
activation of proapoptotic pathways in males but not females
[43, 92, 94]. Males harboring the R403Q mutation show
progressive deterioration in ventricular function associated
with chamber dilation whereas females R403Q mice do not
[92, 95, 96].
At the myoﬁlament level, a recent study reports that
demembranated (permeabilized) cardiac ﬁbers from males
develop more tension at a given [Ca2+]c o m p a r e dt of e m a l e s
indicating that the contractile apparatus is more sensitive to
Ca2+ in males [63]. Moreover, the R403Q mutation does not
impact Ca2+-sensitive tension development in cardiac ﬁbers
when compared to controls from either sex. Using another
R403Q transgenic model, we ﬁnd that Ca2+-sensitivity is
similarly greater in males compared to females and that
the R403Q mutation does not impact Ca2+-sensitivity in
males only (unpublished observations). However, cardiac
muscle from female mice expressing the R403Q mutation is
signiﬁcantly more sensitive to Ca2+ than controls and both
WT and R403Q cardiac ﬁbers from males.
Again, the factors underlying the diﬀerences between
our data and the previous report are the unique timepoints
during disease progression at which the experiments were
performed. In the comparable study by Palmer et al. (2008),
measurements were performed in ﬁbers taken from animals
that were 10–20 weeks of age where mice expressing the
R403Q mutation exhibit no observable HCM pathology
[63, 93]. We performed our studies at 10–12 months of
age, a timepoint where R403Q mice exhibit signiﬁcant HCM
pathology, functional deﬁcits, and sex diﬀerences [92, 95,
96]. The implication from our data is that the increased
Ca2+ sensitivity may provide suﬃcient contractile support
in female R403Q hearts maintaining a compensated state, a
characteristic not exhibited in males.
It is possible that as disease progresses, posttranslational
changes occur to modify Ca2+-sensitivity and ultimately
contribute to the phenotypic and functional diﬀerences
between male and female R403Q mice. Interestingly, previ-
ous reports demonstrate that the R403Q mutation results
in enhanced left-ventricular systolic function accompanied
by compromised left-ventricular diastolic function at an
early timepoint (4–6 months of age) [96–98]. Considering
that females with clinically signiﬁcant CHF typically present
with diastolic dysfunction and preserved (nonimpaired)
systolic function, this particular model may be useful to
more fully elucidate the cellular mechanisms underlying sex
dimorphisms in CHF presentation [28, 29]. As outlined
above, an approach that integrates myoﬁlament function,
cellular signaling, and intact ventricular function at distinct
timepoints during the progression of cardiac disease is
needed. Once again, the context in which these studies are
performed is critical.
5. Sex-DependentImpact of Substrateson
CardiacFunction
When discussing cardiac contractility and CHF, the impact
of energy generation, utilization, and delivery on cardiac
function cannot be ignored. Given the extreme ener-
getic demands, cardiac muscle preferentially fulﬁlls energy
requirements through the oxidation of fatty acids rather
than glucose. On a molar basis, fatty acid oxidation (FAO)
provides the greatest yield of ATP compared to glycolytic
or other substrates such as lactate [99]. However, during
the early stages of pathological cardiac hypertrophy such as
occured in HCM where cardiac function is not compro-
mised, substrate preference in the heart switches to glucose
while FAO either stays the same or decreases [100–102].
As compensated hypertrophy progresses to decompensated
cardiac hypertrophy where severe ventricular dysfunction
ensues, both glycolytic and FAO capacity diminish thereby
decreasing the overall energy reserve in the heart [103–105].
At this point, cardiac energetic pathways no longer display
the plasticity required for adaptation to a diseased state and
contribute to the deterioration of the failing myocardium.
Since the major goal of metabolic pathways in the heart
is to provide a suﬃcient supply of ATP for myocyte function,
it is reasonable to predict that the molecular underpinnings
of the metabolic derangements during cardiac disease or
myocellular metabolism in general display sex diﬀerences.
Clues as to these diﬀerences are revealed from studies using
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of fatty acid metabolism. Pharmacologic inhibition of car-
nitine palmitoyltransferase I (CPT I), a critical regulator in
mitochondrial fatty acid import, is lethal in male mice null
for peroxisome proliferator-activated receptor-α (PPAR-α)
whereas only 25% of female PPAR-α-null mice die [106]. In
mice overexpressing lipoprotein lipase (LPL) in cardiac and
skeletalmusclebutlackingglobalPPAR-α,over50%ofmales
die within 4 months of age while the remaining males do not
survive past 11 months of age [107]. Females, on the other
hand, survive for more than 12 months of age. Interestingly,
the diﬀerences in plasma free fatty acid (FFA) levels as a
result of the genetic manipulations cannot account for the
extreme disparity in mortality [107]. In both sexes of double
transgenics,circulatingFFAiselevatedwhiletriglyceridesare
reduced. Therefore, the implication is that female hearts may
be better adapted to utilize the circulating FFA as a substrate
for myocardial energy utilization or that female hearts are
protected against this elevation in circulating FFA than their
male counterparts.
From the above studies, it appears that there are sex
dimorphisms in the ability to utilize speciﬁc energy sub-
strates. Yet, very little is known regarding any sex dimor-
phisms and the impact of substrates on contractile function.
Consequently, even less is known about how this changes
with cardiac disease progression. The delivery and utilization
of substrates by cardiac muscle cells maintains a dynamic
component such that the ﬂux of these substrates undoubt-
edlyplaysanintegralroleincontractiledynamics.Again,any
sexdimorphismsinsubstrateutilizationnecessitateaneedto
put these data in the context of each sex. Consequently, some
key diﬀerences in lipid metabolism (providing about 95% of
the substrate for cardiac cells) between the sexes need to be
highlighted.
The delivery of these substrates is accomplished through
the circulation, and the release of these substrates depends
onmetabolicmediatorsandtissuesthatincludeliver,adipose
tissue, and muscle. For example, studies have shown that the
basal rate of lipolysis as deﬁned by the rate of appearance of
plasma FFA is greater in women than in men [14, 108]. The
released FFAs will either by oxidized for fuel or stored as TG.
Therefore, VLDL-TG production depends on the availability
of hepatic FFA and thus is a major determinant of VLDL-TG
production[109].ThehigherrateofFFAreleaseisconsistent
with the ﬁnding that women demonstrate higher rates of
VLDL production compared to men, which are unaltered
by obesity like in men [15]. Interestingly, in the same study,
the amount of plasma VLDL-TG between men and women
was similar, suggesting that the rate of VLDL-TG clearance is
greater in women when compared to men [15].
ThesesexdiﬀerencesinVLDL-TGdynamicswerefurther
investigated in a recent study by Magkos et al. (2007) [110].
In this study, the molar ratio between hepatic VLDL-TG
and VLDL-apolipoproteinB-100 (VLDL-apoB-100, which
provides the structural framework of the VLDL particle and
permits the incorporation of TG, cholesterol and cholesterol
esters, and other apolipoproteins before VLDL secretion
occurs [111]) was determined in age-matched lean men and
women [110]. The authors ﬁnd a greater molar ratio of
hepatic VLDL-TG and VLDL-apolipoproteinB-100 secretion
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Figure 2: Schematic representation of VLDL and FFA ﬂux. Women
demonstratehigherratesofFFAreleaseasaresultofhigherlipolytic
rates when compared to men. This is consistent with elevated
rates of VLDL production and clearance in women. In addition,
the molar ratio between hepatic VLDL-TG and VLDL-apoB-100
was greater in women compared to men suggesting that women
secrete larger, more TG-rich VLDL particles than men, which may
contribute to some of the observed sex dimorphisms.
rates in women compared to men. Because only one
apolipoproteinB-100 molecule is found in a VLDL particle
[112], the suggestion from these data is that the liver in
women secretes larger VLDL particles containing more TG
than those secreted by men [110]. A potential mechanism
underlying these diﬀerences in VLDL-TG secretion and
clearance rates between men and women begins with the
observation that the lipolysis of TG that are in large, TG-rich
lipoproteins is more eﬃcient than lipolysis of TG in small,
TG-poor particles [113]. Since the hydrolysis of lipoproteins
including VLDL particles is largely mediated by lipoprotein
lipase(LPL)inmuscleandadiposetissue[114,115],elevated
LPL activity in females can further explain the diﬀerences
in VLDL dynamics, which has been found in skeletal and
adipose tissue [116, 117] (see Figure 2 for a summary).
Interestingly, estrogen decreases LPL activity in plasma [118]
and adipose tissue [119] in humans and it also inhibits LPL
transcriptional activity [120].
From the above discussion, it is apparent that there
are sex diﬀerences in lipid metabolism and substrate ﬂux
through the circulation. There is, however, a lack of study
directly examining how these sex dimorphisms impact
cardiac function and potentially translate into a protection
during cardiac disease and CHF. In general, when cardiac
muscle is exposed to fatty acids, contractility decreases
whether measured in isolated cardiac cells [121, 122] or the
whole heart [123, 124]. Recent evidence suggests that thisJournal of Biomedicine and Biotechnology 7
mechanism in intact cardiac cells is through augmentation
of voltage-gated K+ current responsible for repolarization of
the cardiac cell [122]. Interestingly, demembranated cardiac
muscle strips from rainbow trout fed a diet high in omega-3
fatty acid are less sensitive to Ca2+ than those from trout fed
a diet low in omega-3 fatty acid [125]. In contrast to these
results, permeabilized cardiac cells from mice with cardiac-
speciﬁc overexpression of fatty acid transport protein 1,
whichleadstoincreasedfattyaciduptake,accumulation,and
usage, are more sensitive to Ca2+ than wild-type controls
[121]. The inconsistencies in the latter phenomenon using
permeabilized cardiac muscle may be explained by the
diﬀerentialimpactofFFAonintracellularsignalingpathways
such as those including protein kinase A and protein kinase
C[ 126–128].
When looking at cardiac disease and CHF, manipulation
of FFA delivery is controversial. In the long-term, sup-
pression of glycolytic oxidation by increasing FFA delivery
decreases cardiac inotropy [129]. Consequently, lowering
cardiac FAO by reducing circulating FFAs or inhibiting
mediatorsofmitochondrialFFAhasbeensuggestedasather-
apeuticmeasuretoincreasecardiaccontractilityforCHF(for
review see [129]). However, this has been recently challenged
[130,131].Moreimportantly,givensexdimorphismsinlipid
dynamics described above, there are no reports detailing
whether this approach is eﬀective in females. Considering
thatestrogenmayinhibitLPLactivityasdetailedabove[118–
120], it has been hypothesized that estrogen provides protec-
tion against adipogensis and the clinical sequlae associated
with increased adiposity. Therefore, females may exist at an
inotropic state that is distinct from males due to this lack of
FFA delivery in females because of this LPL inhibition and
consequently decreased FFA delivery to myocardial cells.
This particular topic of substrate generation, utilization,
anddeliveryandhowitdiﬀersbetweenthesexesperhapsbest
illustrates the need to understand the impact of lipids on the
heart in the context of sex. For example, FFAs can impact
myocardialcontractilefunctionandsignaling.But,thiseﬀect
will depend on the ﬂux of substrate delivery and metabolism
by the myocardium, which we know is diﬀerent between
males and females. Clearly, the dynamics of lipid metabolism
and the delivery of these substrates to the heart will have a
profound impact on cardiac function and, consequently, sex
diﬀerences in cardiac disease development.
6. Conclusions
Thediﬃcultythatispresentedtothecontemporaryscientiﬁc
investigator is that diﬀerences between males and females
exist. This diﬀerence is clinically relevant; yet there remain
insuﬃcient data to make global recommendations, especially
when it comes to cardiac disease and CHF. The goal of
this review was to highlight that, despite a growing body
of literature describing sex dimorphisms in cardiac disease
and some potential molecular mechanisms underlying these
diﬀerences, there are lingering questions. For example, what
is the relationship between diastolic dysfunction and CHF
andhowisthismodiﬁedbysex?Furthermore,wemustbegin
to deﬁne how comparisons between males and females are
to be presented and whether it is appropriate to perform
studies that directly compare males and females without
providing how these underlying mechanisms operate in the
proper sexual context. Despite implicit diﬃculties with the
study of sex diﬀerences, signiﬁcant advancements deﬁning
sex dimorphisms in CVD and CHF have been made.
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